Universität zu Köln

Kobe, Carsten, Kuhnert, Georg, Kahraman, Deniz, Haverkamp, Heinz ORCID: 0000-0001-6895-4132, Eich, Hans-Theodor, Franke, Mareike, Persigehl, Thorsten, Klutmann, Susanne, Amthauer, Holger, Bockisch, Andreas, Kluge, Regine, Wolf, Hans-Heinrich, Maintz, David, Fuchs, Michael, Borchmann, Peter, Diehl, Volker, Drzezga, Alexander, Engert, Andreas and Dietlein, Markus (2014). Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma. J. Clin. Oncol., 32 (17). S. 1776 - 1782. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Full text not available from this repository.

Abstract

Purpose Positron emission tomography (PET) after chemotherapy can guide consolidating radiotherapy in advanced-stage Hodgkin lymphoma (HL). This analysis aims to improve outcome prediction by integrating additional criteria derived by computed tomography (CT). Patients and Methods The analysis set consisted of 739 patients with residues > 2.5 cm after chemotherapy from a total of 2,126 patients treated in the HD15 trial (HD15 for advanced stage Hodgkin's disease: Quality assurance protocol for reduction of toxicity and the prognostic relevance of fluorodeoxyglucose-positron-emission tomography [FDG-PET] in the first-line treatment of advanced-stage Hodgkin's disease) performed by the German Hodgkin Study Group. A central panel performed image analysis and interpretation of CT scans before and after chemotherapy as well as PET scans after chemotherapy. Prognosis was evaluated by using progression-free survival (PFS); groups were compared with the log-rank test. Potential prognostic factors were investigated by using receiver operating characteristic analysis and logistic regression. Results In all, 548 (74%) of 739 patients had PET-negative residues after chemotherapy; these patients did not receive additional radiotherapy and showed a 4-year PFS of 91.5%. The 191 PET-positive patients (26%) receiving additional radiotherapy had a 4-year PFS of 86.1% (P = .022). CT alone did not allow further separation of patients in partial remission by risk of recurrence (P = .9). In the subgroup of the 54 PET-positive patients with a relative reduction of less than 40%, the risk of progression or relapse within the first year was 23.1% compared with 5.3% for patients with a larger reduction (difference, 17.9%; 95% CI, 5.8% to 30%). Conclusion Patients with HL who have PET-positive residual disease after chemotherapy and poor tumor shrinkage are at high risk of progression or relapse.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kobe, Carsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuhnert, Georg UNSPECIFIED UNSPECIFIED UNSPECIFIED Kahraman, Deniz UNSPECIFIED UNSPECIFIED UNSPECIFIED Haverkamp, Heinz UNSPECIFIED orcid.org/0000-0001-6895-4132 UNSPECIFIED Eich, Hans-Theodor UNSPECIFIED UNSPECIFIED UNSPECIFIED Franke, Mareike UNSPECIFIED UNSPECIFIED UNSPECIFIED Persigehl, Thorsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Klutmann, Susanne UNSPECIFIED UNSPECIFIED UNSPECIFIED Amthauer, Holger UNSPECIFIED UNSPECIFIED UNSPECIFIED Bockisch, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Kluge, Regine UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, Hans-Heinrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Maintz, David UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Diehl, Volker UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietlein, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-435901
DOI:	10.1200/JCO.2013.53.2507
Journal or Publication Title:	J. Clin. Oncol.
Volume:	32
Number:	17
Page Range:	S. 1776 - 1782
Date:	2014
Publisher:	AMER SOC CLINICAL ONCOLOGY
Place of Publication:	ALEXANDRIA
ISSN:	1527-7755
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INTERNATIONAL WORKSHOP; RESPONSE ASSESSMENT; INTERIM-PET; F-18-FDG; DISEASE; ERLOTINIB; STANDARD; CRITERIA; THERAPY; ABVD Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/43590